After back-to-back trial flops, Realm slashes its staff, halts research work and ponders a fire sale
Just days after reporting its second mid-stage trial failure in 5 months, little Realm Therapeutics $RLM is throwing in the towel.
The Phase II …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
